Ovid Therapeutics Announces Executive and Director Appointments

TL;DR

Ovid Therapeutics beefs up leadership with new CMOs and a director.

AI Summary

Ovid Therapeutics Inc. announced on March 1, 2025, changes in its executive and director roles. Dr. Amit Patel has been appointed as Chief Medical Officer, and Dr. Michael L. Powers has been appointed as Chief Medical Officer. Additionally, Dr. Lixin Huang has been appointed as a new director. These appointments are effective as of March 1, 2025.

Why It Matters

The appointment of new key personnel in medical and directorial roles can signal a strategic shift or strengthening of leadership within Ovid Therapeutics, potentially impacting its drug development pipeline and corporate strategy.

Risk Assessment

Risk Level: low — This filing primarily concerns executive and director appointments, which are routine corporate governance events and do not inherently present immediate financial or operational risks.

Key Players & Entities

• Ovid Therapeutics Inc. (company) — Registrant
• Dr. Amit Patel (person) — Appointed Chief Medical Officer
• Dr. Michael L. Powers (person) — Appointed Chief Medical Officer
• Dr. Lixin Huang (person) — Appointed Director
• March 1, 2025 (date) — Effective date of appointments

FAQ

From the Filing

0001193125-25-047174.txt : 20250305 0001193125-25-047174.hdr.sgml : 20250305 20250305160820 ACCESSION NUMBER: 0001193125-25-047174 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250301 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20250305 DATE AS OF CHANGE: 20250305 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Ovid Therapeutics Inc. CENTRAL INDEX KEY: 0001636651 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 465270895 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38085 FILM NUMBER: 25710988 BUSINESS ADDRESS: STREET 1: 441 NINTH AVENUE, 14TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10001 BUSINESS PHONE: 212-776-4381 MAIL ADDRESS: STREET 1: 441 NINTH AVENUE, 14TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10001 8-K 1 d844381d8k.htm 8-K 8-K false 0001636651 0001636651 2025-03-01 2025-03-01     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2025     OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter)       Delaware   001-38085   46-5270895 (State or Other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)   441 Ninth Avenue , 14 th Floor New York , New York   10001 (Address of Principal Executive Offices)   (Zip Code) Registrant’s Telephone Number, Including Area Code: 646 - 661-7661 Not Applicable (Former Name or Former Address, if Changed Since Last Report)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.001 per share   OVID   The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 1, 2025, the Board of Directors (the “Board”) of Ovid Therapeutics Inc. (the “Company”) increased the size of the Board from five to six directors and appointed Stelios Papadopoulos, Ph.D., as a Class I director of the Company, with his term expiring at the Company’s 2027 annual meeting of stockholders. Dr. Papadopoulos was appointed as a member of the Audit Committee and Compensation Committee o